SMWB vs NUVB Comparison

Similarweb Ltd provides a platform for digital intelligence, delivering a trusted, comprehensive, and detailed view of the digital world that empowers customers to accelerate their growth and become more competitive in the markets. Its proprietary technology analyzes billions of digital interactions and transactions every day from millions of websites and apps and turns these digital signals into actionable insights. The company generates revenues mainly from SaaS subscriptions, which comprise subscription fees from customers utilizing cloud-based digital intelligence solutions and other subscription-based solutions. Geographically, the majority of its revenue is derived from the United States and rest from Israel, United Kingdom, Europe, Asia Pacific and other regions.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).